Remarkably, AML patients with DNMT3A mutations have shorter survival than DNMT3AWT patients, and this effect seems to be independent of the characteristic late co-mutations in FLT3 or NPM1 [6]. The mutant DNMT3AR882X protein induces epigenetic changes in HSCs that distort the balance between self-renewal and differentiation [7,8], however detailed knowledge about the downstream targets of these changes remains scarce [9]. This evidence concerns the gene DNMT3A and acute myeloid leukemia.